CEFTAZIDIME

category:
203
CEFTAZIDIM
CALCUTIONS AREA
CLICK ON CALCULATOR

Infant Data


PMA= gestational age plus postnatal age

Results

MEDICAL INFORMATIONS

INDICATIONS

  • Treatment of neonatal meningitis and sepsis: caused by susceptible gram-negative organisms (e.g. E coli, H influenzae, Neisseria, Klebsiella, and Proteus species), especially Pseudomonas aeruginosa. Resistance among strains ofSerratia and Enterobacteriaceae is increasing.
  • Infective Endocarditis: The following recommendations are based on a consensus of experts . The full pediatric guidelines can be found here:

ADVERSE EFFECTS

Reported adverse effects are uncommon but include rash, diarrhea, elevated hepatic transaminases, eosinophilia, and positive Coombs’ test. In a prospective cohort study (n=4579), third generation cephalosporins started by day 3 of life in extremely low birth weight infants (less than 1000 g) were associated with a significantly increased risk of candidiasis compared with other antibiotics.

ADMINISTRATION

Intravenous:

  • IV push over 3 to 5 minutes at a maximum concentration of 100 mg/mL or 200 mg/mL .
  • Intermittent IV infusion over 30 minutes at a concentration of 1 to 40 mg/mL as well as 50 mg/mL.

Intramuscular:

  • Deep IM administration into a large muscle mass for less serious infections.

MONITORING

Measuring serum concentration is not usually necessary.